Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma

doi:10.3748/wjg.v23.i18.3301

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8260)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

621

WORD

327

HTML

3832

Figures (1-2)

227

Tables (1-5)

203

Sum=5210

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1120

Download

1930

Sum=3050

May 14, 2017 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 14, 2017; 23(18): 3301-3308
Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3301

Table 2 Summary of neoadjuvant chemoradiotherapy n (%)

	Neoadjuvant chemoradiotherapy (n = 12)
Regimen of chemotherapy
5-fluorouracil + leucovorin	5 (41.7)
Gemcitabine	5 (41.7)
Gemcitabine + cisplatin	1 (8.3)
Tegfur/Uracil (UFT)	1 (8.3)
Total dose of radiotherapy (cGy)	5040 (4545, 5040)¹
Response in follow-up image
Partial response	7 (58.3)
Stable disease	5 (41.7)
Complete response in pathology	2 (16.7)
Downstaging of TNM stage	4 (33.3)
Toxicity
≥ Grade II	2 (16.7)

¹Continuous variables were denoted median (Q1, Q3) and categorical variables were denoted number (%).

Citation: Jung JH, Lee HJ, Lee HS, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Bang S. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol 2017; 23(18): 3301-3308
URL: https://www.wjgnet.com/1007-9327/full/v23/i18/3301.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i18.3301